Patient perspectives on buprenorphine/naloxone: A qualitative study of retention during the starting treatment with agonist replacement therapies (START) study

Journal of Psychoactive Drugs

Volumn 46, Issue 5, 2014, Pages 412-426

  Teruya, Cheryl ^a   Schwartz, Robert P ^b   Mitchell, Shannon Gwin ^c   Hasson, Albert L ^a   Thomas, Christie ^a   Buoncristiani, Samantha H ^a   Hser, Yih Ing ^a   Wiest, Katharina ^d   Cohen, Allan J ^e   Glick, Naomi ^a   Jacobs, Petra ^g   McLaughlin, Paul ^f   Ling, Walter ^a  

^a Friends Research Institute ^*  (United States)

^b FRIENDS RESEARCH INSTITUTE   (United States)

^c Social Research Center   (United States)

^d Bay Area Addiction Research & Treatment ^*  (United States)

^e Bay Area Addiction Research and Treatment   (United States)

^f NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^g Hartford Dispensary   (United States)

Author keywords

Buprenorphine; Patient perspectives; Qualitative; Retention

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE; BUPRENORPHINE; NALOXONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; PATIENT TRANSPORT; PHASE 4 CLINICAL TRIAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SEMI STRUCTURED INTERVIEW; UNSPECIFIED SIDE EFFECT; METHODOLOGY; OPIOID-RELATED DISORDERS; QUALITATIVE RESEARCH;

ADULT; BUPRENORPHINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; OPIOID-RELATED DISORDERS; QUALITATIVE RESEARCH; RESEARCH DESIGN;

EID: 84964314440     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2014.921743     Document Type: Article

References (71)

1. Al-Tayyib, A.A. & Koester, S. 2011. Injection drug users’ experience with and attitudes toward methadone clinics in Denver, CO. Journal of Substance Abuse Treatment 41 (1): 30-6.
2. Awgu, E.; Magura, S. & Rosenblum, A. 2010. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. Journal of Psychoactive Drugs 42 (3): 339-46.
3. Ball, J.C. & Ross, A. 1991. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome. New York: Springer-Verlag.
4. Barry, D.T.; Irwin, K.S.; Jones, E.S.; Becker, W.C.; Tetrault, J.M.; Sullivan, L.E.; Hansen, H.; O’Connor, P.G.; Schottenfeld, R.S. & Fiellin, D.A. 2009. Integrating buprenorphine treatment into officebased practice: A qualitative study. Journal of General Internal Medicine 24 (2): 218-25.
5. Bazazi, A.R.; Yokell, M.; Fu, J.J.; Rich, J.D. & Zaller, N.D. 2011. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. Journal of Addiction Medicine 5 (3): 175-80.
6. Bechtel, C. & Ness, D.L. 2010. If you build it, will they come? Designing truly patient-centered health care. Health Affairs 29 (5): 914-20.
7. Bell, J.; Trinh, L.; Butler, B.; Randall, D. & Rubin, G. 2009. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 104 (7): 1193-200.
8. Binswanger, I.A.; Stern, M.F.; Deyo, R.A.; Heagerty, P.J.; Cheadle, A.; Elmore, J.G. & Koepsell, T.D. 2007. Release from prison: A high risk of death for former inmates. New England Journal of Medicine 356 (2): 157-65.
9. Booth, R.E.; Corsi, K.F. & Mikulich-Gilbertson, S.K. 2004. Factors associated with methadone maintenance treatment retention among street-recruited injection drug users. Drug and Alcohol Dependence 74 (2): 177-85.
10. Boyatzis, R.E. 1998. Thematic Analysis and Code Development: Transforming Qualitative Information. Thousand Oaks, CA: Sage.
11. Caplehorn, J.R.; Dalton, M.S.; Haldar, F.; Petrenas, A.M. & Nisbet, J.G. 1996. Methadone maintenance and addicts’ risk of fatal heroin overdose. Substanc Use and Misuse 31 (2): 177-196.
12. Center for Substance Abuse Treatment. 2004. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration.
13. Connock, M.; Juarez-Garcia, A.; Jowett, S.; Frew, E.; Liu, Z.; Taylor, R.J.; Fry-Smith, A.; Day, E.; Lintzeris, N.; Roberts, T.; Burls, A. & Taylor, R.S. 2007. Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation. Health Technology Assessment 11 (9): 1-171, iii-iv.
14. Coviello, D.M.; Zanis, D.A.; Wesnoski, S.A. & Alterman, A.I. 2006. The effectiveness of outreach case management in re-enrolling discharged methadone patients. Drug and Alcohol Dependence 85 (1): 56-65.
15. Creswell, J.W. 2003. Research Design: Qualitative, Quantitative, and Mixed Methods Approaches, 2nd ed. Thousand Oaks, CA: Sage.
16. Deck, D. & Carlson, M.J. 2005. Retention in publicly funded methadone maintenance treatment in twoWestern States. Journal of Behavioral Health Services and Research 32 (1): 43-60.
17. Demetrovics, Z.; Farkas, J.; Csorba, J.; Nemeth, A.; Mervo, B.; Szemelyacz, J.; Fleischmann, E.; Kassai-Farkas, A.; Petke, Z.; Orojan, T.; Rozsa, S.; Rigo, P.; Funk, S.; Kapitany, M.; Kollar, A. & Racz, J. 2009. Early experience with Suboxone maintenance therapy in Hungary. Neuropsychopharmacologia Hungarica 11 (4): 249-57.
18. Ducharme, L.J. & Abraham, A.J. 2008. State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment Prevention Policy 3: 17.
19. Egan, J.E.; Netherland, J.; Gass, J.; Finkelstein, R.; Weiss, L. & Collaborative, B. 2011. Patient perspectives on buprenorphine/naloxone treatment in the context of HIV care. Journal of Acquired Immune Deficiency Syndromes 56 Suppl 1: S46-53.
20. Fareed, A.; Vayalapalli, S.; Casarella, J. & Drexler, K. 2012. Treatment outcome for flexible dosing buprenorphine maintenance treatment. American Journal of Drug and Alcohol Abuse 38 (2): 155-60.
21. Fischer, G.; Gombas, W.; Eder, H.; Jagsch, R.; Peternell, A.; Stuhlinger, G.; Pezawas, L.; Aschauer, H.N. & Kasper, S. 1999. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 94 (9): 1337-47.
22. Friedman, H.; Newton, C. & Klein, T.W. 2003. Microbial infections, immunomodulation, and drugs of abuse. Clinical Microbiology Reviews 16 (2): 209-19.
23. Fudala P.J.; Bridge, T.P.; Herbert, S.; Williford, W.O.; Chiang, C.N.; Jones, K.; Collins, J.; Raisch, D.; Casadonte, P.; Goldsmith, R.J.; Ling, W.; Malkerneker, U.; McNicholas, L.; Renner, J.; Stine, S.; Tusel, D. & Group., B.N.C.S. 2003. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. New England Journal of Medicine 349 (10): 949-58.
24. Glaser, B.G. & Strauss, A.L. 1967. The Discovery of Grounded Theory. New York: Aldine de Gruyter.
25. Gossop, M.; Marsden, J.; Stewart, D. & Kidd, T. 2003. Reduction or cessation of injecting risk behaviours? Treatment outcomes at 1-year follow-up. Addictive Behaviors 28 (4): 785-93.
26. Hser, Y.; Joshi, V.; Maglione, M.; Chou, C. & Anglin, D. 2001. Effects of program and patient characteristics on retention of drug treatment patients. Evaluation and Program Planning 24: 331-341.
27. Hser, Y.I. 2007. Predicting long-term stable recovery from heroin addiction: Findings from a 33-year follow-up study. Journal of Addictive Diseases 26 (1): 51-60.
28. Hubbard, R.L.; Craddock, S.G.; Flynn, P.M.; Anderson, J. & Etheridge, R.M. 1997. Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study (DATOS). Psychology of Addictive Behaviors 11 (4): 261-278.
29. Hubbard, R.L., Craddock, S. G., Anderson, J. 2003. Overview of 5-year follow-up outcomes in the Drug Abuse Treatment Outcome Studies (DATOS). Journal of Substance Abuse Treatment 25 (3): 125-134.
30. Huberman, A.M. & Miles, M.B. 1994. Data management and analysis methods. In: N. K. Denzin & Y. S. Lincoln (Eds.) Handbook of Qualitative Research. Thousand Oaks, CA: Sage.
31. Institute of Medicine. 2001. Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press.
32. Joe, G.W.; Simpson, D.D. & Broome, K.M. 1998. Effects of readiness for drug abuse tratment on client retention and assessment of process. Addiction 93 (8): 1177-90.
33. Johnson, R.E.; Chutuape, M.A.; Strain, E.C.; Walsh, S.L.; Stitzer, M.L. & Bigelow, G.E. 2000. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. New England Journal of Medicine 343 (18): 1290-7.
34. Johnson, R.E. & McCagh, J.C. 2000. Buprenorphine and naloxone for heroin dependence. Current Psychiatry Reports 2 (6): 519-26.
35. Jones, H.E. 2004. Practical considerations for the clinical use of buprenorphine. Science & Practice Perspectives 2 (2): 4-20.
36. Kamien, J.B.; Branstetter, S.A. & Amass, L. 2008. Buprenorphinenaloxone versus methadone maintenance therapy: A randomised double-blind trial with opioid-dependent patients Heroin Addiction and Related Clinical Problems 10 (4): 5-8.
37. Kelly, S.M.; O’Grady, K.E.; Mitchell, S.G.; Brown, B.S. & Schwartz, R.P. 2011. Predictors of methadone treatment retention from a multisite study: A survival analysis. Drug and Alcohol Dependence 117 (2-3): 170-5.
38. Kimber, J.; Copeland, L.; Hickman, M.; Macleod, J.; McKenzie, J.; De Angelis, D. & Robertson, J.R. 2010. Survival and cessation in injecting drug users: Prospective observational study of outcomes and effect of opiate substitution treatment. British Medical Journal 341: c3172.
39. Koester, S.; Anderson, K. & Hoffer, L. 1999. Active heroin injectors’ perceptions and use of methadone maintenance treatment: Cynical performance or self-prescribed risk reduction? Substance Use and Misuse 34 (14): 2135-53.
40. Kosten, T.R. 1994. Buprenorphine for benzodiazepineabusing heroin addicts. American Journal of Psychiatry 151 (1): 151.
41. Kristensen, O.; Espegren, O.; Asland, R.; Jakobsen, E.; Lie, O. & Seiler, S. 2005. Buprenorphine and methadone to opiate addicts: A randomized trial. Tidsskrift for den Norske Laegeforening 125 (2): 148-51.
42. Ling, W.; Charuvastra, C.; Collins, J.F.; Batki, S.; Brown, L.S Jr; Kintaudi, P.; Wesson, D.R.; McNicholas, L.; Tusel, D.J.; Malkerneker, U.; Renner, J.A Jr; Santos, E.; Casadonte, P.; Fye, C.; Stine, S.; Wang, R.I. & Segal, D. 1998. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 93 (4): 475-86.
43. Ling, W.; Wesson, D.R.; Charuvastra, C. & Klett, C.J. 1996. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Archives of General Psychiatry 53 (5): 401-7.
44. Magura, S.; Nwakeze, P.C. & Demsky, S.Y. 1998. Pre-and in-treatment predictors of retention in methadone treatment using survival analysis. Addiction 93 (1): 51-60.
45. Mattick, R.P.; Ali, R.; White, J.M.; O’Brien, S.; Wolk, S. & Danz, C. 2003. Buprenorphine versus methadone maintenance therapy: A randomized double-blind trial with 405 opioid-dependent patients. Addiction 98 (4): 441-52.
46. Mattick, R.P.; Kimber, J.; Breen, C. & Davoli, M. 2008. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews (2): CD002207.
47. Metzger, D.S.; Woody, G.E.; McLellan, A.T.; O’Brien, C.P.; Druley, P.; Navaline, H.; DePhilippis, D.; Stolley, P. & Abrutyn, E. 1993. Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: An 18-month prospective follow-up. Journal of Acquired Immune Deficiency Syndromes 6 (9): 1049-1056.
48. Mitchell, S.G.; Gryczynski, J.; Schwartz, R.P.; O’Grady, K.E.; Olsen, Y.K. & Jaffe, J.H. 2012. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug and Alcohol Dependence 128 (3): 222-29.
49. Mitchell, S.G.; Kelly, S.M.; Brown, B.S.; Reisinger, H.S.; Peterson, J.A.; Ruhf, A.; Agar, M.H. & Schwartz, R.P. 2009. Incarceration and opioid withdrawal: The experiences of methadone patients and outof-treatment heroin users. Journal of Psychoactive Drugs 41 (2): 145-52.
50. Patton, M.Q. 1990. Qualitative Research and Evaluation Methods. Newbury Park, CA: Sage.
51. Ponizovsky, A.M. & Grinshpoon, A. 2007. Quality of life among heroin users on buprenorphine versus methadone maintenance. American Journal of Drug and Alcohol Abuse 33 (5): 631-42.
52. Reisinger, H.S.; Schwartz, R.P.; Mitchell, S.G.; Peterson, J.A.; Kelly, S.M.; O’Grady, K.E.; Marrari, E.A.; Brown, B.S. & Agar, M.H. 2009. Premature discharge from methadone treatment: Patient perspectives. Journal of Psychoactive Drugs 41 (3): 285-96.
53. Rhoades, H.M.; Creson, D.; Elk, R.; Schmitz, J. & Grabowski, J. 1998. Retention, HIV risk, and illicit drug use during treatment: Methadone dose and visit frequency. American Journal of Public Health 88 (1): 34-9.
54. Ronald, P.J.; Robertson, J.R. & Elton, R.A. 1994. Continued drug use and other cofactors for progression to AIDS among injecting drug users. AIDS 8 (3): 339-43.
55. Saxon, A.J.; Ling, W.; Hillhouse, M.; Thomas, C.; Hasson, A.; Ang, A.; Doraimani, G.; Tasissa, G.; Lokhnygina, Y.; Leimberger, J.; Bruce, R.D.; McCarthy, J.; Wiest, K.; McLaughlin, P.; Bilangi, R.; Cohen, A.; Woody, G. & Jacobs, P. 2013. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: A randomized trial. Drug and Alcohol Dependence 128 (1-2): 71-6.
56. Saxon, A.J.; Wells, E.A.; Fleming, C.; Jackson, T.R. & Calsyn, D.A. 1996. Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. Addiction 91 (8): 1197-209.
57. Schottenfeld, R.S.; Pakes, J.R.; Oliveto, A.; Ziedonis, D. & Kosten, T.R. 1997. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Archives of General Psychiatry 54 (8): 713-20.
58. Schwartz, R.P.; Kelly, S.M.; O’Grady, K.E.; Mitchell, S.G.; Peterson, J.A.; Reisinger, H.S.; Agar, M.H. & Brown, B.S. 2008. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. American Journal on Addictions 17 (5): 396-401.
59. Simpson, D.D. 1981. Treatment for drug abuse: Follow-up outcomes and length of time spent. Archives of General Psychiatry 38 (8): 875-80.
60. Simpson, D.D.; Joe, G.W.; Rowan-Szal, G.A. & Greener, J.M. 1997. Drug abuse treatment process components that improve retention. Journal of Substance Abuse Treatment 14 (6): 565-72.
61. Skinner, M.L.; Haggerty, K.P.; Fleming, C.B.; Catalano, R.F. & Gainey, R.R. 2011. Opiate-addicted parents in methadone treatment: Longterm recovery, health, and family relationships. Journal of Addictive Diseases 30 (1): 17-26.
62. Soyka, M.; Zingg, C.; Koller, G. & Kuefner, H. 2008. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: Results from a randomized study. International Journal of Neuropsychopharmacology 11 (5): 641-53.
63. Specter, S. 1994. Drugs of abuse and infectious diseases. Journal of the Florida Medical Association 81 (7): 485-7.
64. Strain, E.C.; Stitzer, M.L.; Liebson, I.A. & Bigelow, G.E. 1994. Comparison of buprenorphine and methadone in the treatment of opioid dependence. American Journal of Psychiatry 151 (7): 1025-30.
65. Strain, E.C.; Stitzer, M.L.; Liebson, I.A. & Bigelow, G.E. 1996. Buprenorphine versus methadone in the treatment of opioid dependence: Self-reports, urinalysis, and addiction severity index. Journal of Clinical Psychopharmacology 16 (1): 58-67.
66. Teesson, M.; Mills, K.; Ross, J.; Darke, S.; Williamson, A. & Havard, A. 2008. The impact of treatment on 3 years’ outcome for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS). Addiction 103 (1): 80-8.
67. United States Department of Health and Human Services 2012. Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction: Proposed Modification of Dispensing Restrictions for Buprenorphine and Buprenorphine Combination as Used in Approved Opioid Treatment Medications. Washington, DC: Substance Abuse and Mental Health Services Administration.
68. Wallen, M.C.; Lorman, W.J. & Gosciniak, J.L. 2006. Combined buprenorphine and chlonidine for short-term opiate detoxification: Patient perspectives. Journal of Addictive Diseases 25 (1): 23-31.
69. Winstock, A.R.; Lintzeris, N. & Lea, T. 2011. “Should I stay or should I go?” Coming off methadone and buprenorphine treatment. International Journal of Drug Policy 22 (1): 77-81.
70. Xiao, L.; Wu, Z.; Luo, W. & Wei, X. 2010. Quality of life of outpatients in methadone maintenance treatment clinics. Journal of Acquired Immune Deficiency Syndromes 53 Suppl 1: S116-20.
71. Zhang, Z.; Friedmann, P.D. & Gerstein, D.R. 2003. Does retention matter? Treatment duration and improvement in drug use. Addiction 98: 673-684.